Literature DB >> 23948230

Measles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogens.

Ianko D Iankov1, Mark J Federspiel, Evanthia Galanis.   

Abstract

Helicobacter pylori neutrophil-activating protein (NAP) is a toll-like receptor 2 (TLR2) agonist and potent immunomodulator inducing Th1-type immune response. Here we present data about characterization of the humoral immune response against NAP-tagged antigens, encoded by attenuated measles virus (MV) vector platform, in MV infection susceptible type I interferon receptor knockout and human CD46 transgenic (Ifnarko-CD46Ge) mice. Immunogenicity of MV expressing a full-length human immunoglobulin lambda light chain (MV-lambda) was compared to that of MV expressing lambda-NAP chimeric protein (MV-lambda-NAP). MV-lambda-NAP immunized Ifnarko-CD46Ge mice developed significantly higher (6-20-fold) anti-lambda ELISA titers as compared to the MV-lambda-immunized control animal group, indicating that covalently-linked NAP co-expression significantly enhanced lambda immunogenicity. In contrast, ELISA titers against MV antigens were not significantly different between the animals vaccinated with MV-lambda or MV-lambda-NAP. NAP-tagged antigen expression did not affect development of protective anti-measles immunity. Both MV-lambda and MV-lambda-NAP-immunized groups showed strong virus neutralization serum titers in plaque reduction microneutralization test. These results demonstrated that MV-encoded lambda-NAP is highly immunogenic as compared to the unmodified full-length lambda chain. Boost of immune response to poor immunogens using live vectors expressing NAP-tagged chimeric antigens is an attractive approach with potential application in immunoprophylaxis of infectious diseases and cancer immunotherapy.
Copyright © 2013. Published by Elsevier Ltd.

Entities:  

Keywords:  Chimeric antigens; Helicobacter pylori; Immunogenicity; Measles virus vaccine; Neutrophil-activating protein

Mesh:

Substances:

Year:  2013        PMID: 23948230      PMCID: PMC3903391          DOI: 10.1016/j.vaccine.2013.07.085

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  43 in total

1.  Ab and T cell epitopes of influenza A virus, knowledge and opportunities.

Authors:  Huynh-Hoa Bui; Bjoern Peters; Erika Assarsson; Innocent Mbawuike; Alessandro Sette
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-02       Impact factor: 11.205

Review 2.  Co-stimulatory agonists as immunological adjuvants.

Authors:  Tom A Barr; Jennifer Carlring; Andrew W Heath
Journal:  Vaccine       Date:  2006-02-24       Impact factor: 3.641

3.  Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response.

Authors:  Ianko D Iankov; Manoj Pandey; Mary Harvey; Guy E Griesmann; Mark J Federspiel; Stephen J Russell
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins.

Authors:  Man Ki Song; Christofer J Vindurampulle; Alejandra V E Capozzo; Jeffrey Ulmer; John M Polo; Marcela F Pasetti; Eileen M Barry; Myron M Levine
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Enhanced immunogenicity of hepatitis B surface antigen by insertion of a helper T cell epitope from tetanus toxoid.

Authors:  M V Chengalvala; R A Bhat; B M Bhat; S K Vernon; M D Lubeck
Journal:  Vaccine       Date:  1999-03-05       Impact factor: 3.641

6.  Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus.

Authors:  W P Duprex; S McQuaid; L Hangartner; M A Billeter; B K Rima
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

7.  The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses.

Authors:  Amedeo Amedei; Andrea Cappon; Gaia Codolo; Anna Cabrelle; Alessandra Polenghi; Marisa Benagiano; Elisabetta Tasca; Annalisa Azzurri; Mario Milco D'Elios; Gianfranco Del Prete; Marina de Bernard
Journal:  J Clin Invest       Date:  2006-03-16       Impact factor: 14.808

8.  A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge.

Authors:  Jorge Reyes del Valle; Patricia Devaux; Gregory Hodge; Nicholas J Wegner; Michael B McChesney; Roberto Cattaneo
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

9.  Attenuated measles virus as a vaccine vector.

Authors:  Armando Zuniga; Zili Wang; Matthias Liniger; Lars Hangartner; Michael Caballero; Jovan Pavlovic; Peter Wild; Jean Francois Viret; Reinhard Glueck; Martin A Billeter; Hussein Y Naim
Journal:  Vaccine       Date:  2007-02-02       Impact factor: 3.641

Review 10.  Preparation of recombinant vaccines.

Authors:  Eric Soler; Louis-Marie Houdebine
Journal:  Biotechnol Annu Rev       Date:  2007
View more
  9 in total

Review 1.  Helicobacter pylori neutrophil-activating protein: from molecular pathogenesis to clinical applications.

Authors:  Hua-Wen Fu
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

2.  CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers.

Authors:  Chuan Jin; Jing Ma; Mohanraj Ramachandran; Di Yu; Magnus Essand
Journal:  Nat Biomed Eng       Date:  2022-04-04       Impact factor: 29.234

3.  Establishment of an efficient reverse genetic system of Mumps virus S79 from cloned DNA.

Authors:  Duo Zhou; Meng-Ying Zhu; Yi-Long Wang; Xiao-Qiang Hao; Dong-Ming Zhou; Rong-Xian Liu; Chu-Di Zhang; Chu-Fan Qu; Zheng-Yan Zhao
Journal:  World J Pediatr       Date:  2019-08-28       Impact factor: 2.764

4.  Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with an H . pylori immunostimulatory bacterial transgene.

Authors:  Kimberly B Viker; Michael B Steele; Ianko D Iankov; Susanna C Concilio; Arun Ammayappan; Brad Bolon; Nathan J Jenks; Matthew P Goetz; Eleni Panagioti; Mark J Federspiel; Minetta C Liu; Kah Whye Peng; Evanthia Galanis
Journal:  Mol Ther Methods Clin Dev       Date:  2022-07-31       Impact factor: 5.849

5.  MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer.

Authors:  Hans Martin Singh; Mathias Felix Leber; Sascha Bossow; Christine E Engeland; Jan Dessila; Christian Grossardt; Karim Zaoui; John C Bell; Dirk Jäger; Christof von Kalle; Guy Ungerechts
Journal:  Mol Ther Oncolytics       Date:  2021-05-05       Impact factor: 7.200

6.  Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.

Authors:  Eleni Panagioti; Cheyne Kurokawa; Kimberly Viker; Arun Ammayappan; S Keith Anderson; Sotiris Sotiriou; Kyriakos Chatzopoulos; Katayoun Ayasoufi; Aaron J Johnson; Ianko D Iankov; Evanthia Galanis
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 14.808

7.  Wild-type measles viruses with non-standard genome lengths.

Authors:  Bettina Bankamp; Chunyu Liu; Pierre Rivailler; Jayati Bera; Susmita Shrivastava; Ewen F Kirkness; William J Bellini; Paul A Rota
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

8.  Live Attenuated Measles Virus Vaccine Expressing Helicobacter pylori Heat Shock Protein A.

Authors:  Ianko D Iankov; Cheyne Kurokawa; Kimberly Viker; Steven I Robinson; Arun Ammayappan; Eleni Panagioti; Mark J Federspiel; Evanthia Galanis
Journal:  Mol Ther Oncolytics       Date:  2020-09-23       Impact factor: 7.200

9.  Concurrent expression of HP-NAP enhances antitumor efficacy of oncolytic vaccinia virus but not for Semliki Forest virus.

Authors:  Jing Ma; Chuan Jin; Matko Čančer; Hai Wang; Mohanraj Ramachandran; Di Yu
Journal:  Mol Ther Oncolytics       Date:  2021-05-05       Impact factor: 7.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.